A single-center experience of safety and effectiveness of adjustable intragastric balloon in patients with super obesity.

Background: The Spatz3® Intragastric Adjustable Balloon (SAB) offers a novel approach to weight loss in super obese patients [body mass index (BMI) ≥50 kg/m2]. This study evaluates the safety, effectiveness, and predictors of success of SAB in this population.

Methods: A retrospective study was conducted at King Abdullah Medical City, Makkah, Saudi Arabia, involving 94 patients with SAB implantation.